The post Why Did Moderna Stock Crash 17% Despite Positive Cancer Vaccine Results? appeared first on Coinpedia Fintech News

Moderna stock suffered a sharp panic drop on Thursday, falling 17.57% to close at $202.63 despite promising results from its experimental personalized cancer vaccine. The sell-off followed the early publication of Phase 3 trial data for intismeran autogene, developed in partnership with Merck. The treatment demonstrated a meaningful reduction in melanoma recurrence risk, but investors …